Generic tacrolimus in solid organ transplantation

Clinical Transplantation

Volumn 28, Issue 5, 2014, Pages 623-632

  Taube, D ^a   Jones, G ^b   O'Beirne, J ^b   Wennberg, L ^c   Connor, A ^d   Rasmussen, A ^e   Backman, L ^f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d DERRIFORD HOSPITAL   (United Kingdom)

^e Rigshospitalet   (Denmark)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bioequivalence; Conversion; de novo; Efficacy; Generic; Heart; Kidney; Liver; Safety; Tacrolimus

Indexed keywords

GENERIC DRUG; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ABNORMAL DREAMING; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; FLU LIKE SYNDROME; GRAFT RECIPIENT; GRAFT REJECTION; HEADACHE; HEART GRAFT; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NAUSEA; ORGAN TRANSPLANTATION; OROPHARYNX PAIN; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SQUAMOUS CELL CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; PROGNOSIS; THERAPEUTIC EQUIVALENCE;

DRUGS, GENERIC; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PROGNOSIS; TACROLIMUS; THERAPEUTIC EQUIVALENCY;

EID: 84899971390     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12336     Document Type: Article

References (37)

1. EMA. Guideline on clinical investigation of immunosuppressants for solid organ transplantation. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003593.pdf (accessed 24 July 2008).
2. NICE. Renal transplantation - immunosuppressive regimens (adults). TA 85. London, NICE 2004. Available from: http://guidance.nice.org.uk/TA85/Guidance/pdf/English (accessed 1 June 2013).
3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004: 351: 2715.
4. Summary of Product Characteristics. Adoport 0.5 mg, 1 mg, 5 mg hard capsules. Available from: www.emc.medicines.org.uk (accessed 1 July 2013).
5. Summary of Product Characteristics. Intas 0.5 mg, 1 mg hard capsules. Available from: http://www.sukl.cz (accessed 13 December 2013).
6. Public Assessment Reports For Various Generic Tacrolimus Formulations (PharOS). Available from: http://www.mhra.gov.uk (accessed 13 December 2013).
7. Tacrolimus Capsule [Accord Healthcare, Inc.]. Available from: http://dailymed.nlm.nih.gov (accessed 13 December 2013).
8. EMA. Guideline on the investigation of bioequivalence. 20 January 2010. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (accessed 31 October 2012).
9. van Gelder T. European Society for Organ Transplantation advisory committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int 2011: 24: 1135.
10. Public Assessment Report of the Medicines Evaluation Board in the Netherlands; Tacrolimus Sandoz 0.5 mg, 1.0 mg and 5 mg capsules. NL/H/1340/001-003/DC/1 Feb 2010. Available from: http://db.cbg-meb.nl/mri/par/nlh-1342-001-002-003.pdf (accessed 27 May 2013).
11. Mathew P, Mandal J, Patel K et al. Bioequivalence of two tacrolimus formulations under fasting conditions in healthy male subjects. Clin Ther 2011: 33: 1105.
12. Herranz M, Morales-Alcelay S, Corredera-Hernández MT et al. Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison. Eur J Clin Pharmacol 2013: 69: 1157.
13. Summary of Product Characteristics: Prograf 0.5 mg, 1 mg, 5 mg hard capsules. Available from: www.emc.medicines.org.uk (accessed 1 June 2013).
14. Klintmalm GB. Immunosuppression, generic drugs and the FDA. Am J Transplant 2011: 11: 1765.
15. Ensor CR, Trofe-Clark J, Gabardi S, McDevitt-Potter LM, Shullo MA. Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy 2011: 31: 1111.
16. Alloway RA, Isaacs R, Lake K et al. Report of the american society of transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003: 3: 1211.
17. Harrison JJ, Schiff JR, Coursol CJ et al. Generic immunosuppression in solid organ transplantation: a Canadian perspective. Transplantation 2012: 93: 657.
18. Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH. Drug substitution in transplantation: A National Kidney Foundation White Paper. Am J Kidney Dis 1999: 33: 389.
19. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004: 43: 623.
20. Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Bloom RD. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 2012: 12: 2825.
21. Dick TB, Raines AA, van Der Werf W, Alonso D, Fujita S, Stinson JB. Comparison of dose requirements of Sandoz™ generic tacrolimus with brand innovator drug in kidney transplant recipients. Am J Transplant 2011: 11(S2): Abstract 1102.
22. Connor A, Prowse A, MacPhee I, Rowe PA. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate marker for drug exposure. Transplantation 2012: 93: e45.
23. ® preparations of tacrolimus. Clin Kidney J 2012: 6: 21.
24. ®). Am J Transplant 2012: 12(Suppl s3): Abstract 713.
25. Cheung M, Rodrigues S, Dannhorn E et al. Use of de novo generic tacrolimus in liver transplantation is safe and effective but results in a change in prescribing behaviour which may reduce cost savings. Liver Transpl 2013: 19: S149.
26. McDevitt-Potter LM, Sadaka B, Tichy EM, Rogers CC, Gabardi S. A multicenter experience with generic tacrolimus conversion. Transplantation 2011: 92: 653.
27. Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A, Venkataramanan R. The impact of conversion from Prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 2011: 11: 1861.
28. Raghu VK, Momper JD, Shonder K et al. The effect of generic substitution of tacrolimus in liver and kidney transplant recipients. TTS Congress Berlin, 2012. Abstract 9-PO17.
29. ®) substitution in kidney and pancreas transplantation. Am J Transplant 2012: 12(Suppl s3): Abstract 1294.
30. Shui KY, Rezk T, Henry J et al. Programmed switch of renal transplant recipients from branded to generic tacrolimus is safe, well-tolerated and cost effective. Presented at British Thoracic Society 2013. Abstract P20.
31. Spence MM, Nguyen LM, Hui RL, Chan J. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy 2012: 32: 981.
32. Rosenborg S, Nordström A, Almquist T, Wennberg L, Bárány P. Systematic conversion to generic tacrolimus in stable kidney transplant patients. Abstract presented at 13th International Conference of Therapeutic Drug Monitoring and Clinical Toxicology. Salt Lake City, UT, 2013.
33. Jogia P, Oskiera D, Booth S, McKane W. Generic switch of tacrolimus in prevalent kidney transplant recipients. Abstract presented at ATC 2013. Abstract A635.
34. Dhungel V, Colvin-Adams MM, Eckman PM. Short-term outcomes in heart transplant recipients treated with generic tacrolimus compared to Prograf. Open J Organ Transpl Surg 2013: 3: 19.
35. Summary of Product Characteristics. Adoport® 0.5 mg hard capsules. Available from: www.emc.medicines.org.uk (accessed 1 June 2013).
36. Parker K, Zagadailov EA, Bruno AS, Wiland AM. Transplant coordinators' perceived impact of availability of multiple generic immunosuppression therapies on patients, workload, and posttransplant maintenance therapy. J Transplant 2013: 2013: 897434. doi: 10.1155/2013/897434. Epub 2013 Jan 8.
37. MHRA. Oral tacrolimus products: measures to reduce risk of medication errors. MHRA Drug Saf Update 2010: 3: 5.